6566 Stock Overview
Chuang Yi Biotech Co., ltd. engages in the research, development, and marketing of medicines and health foods in Taiwan. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Chuang Yi Biotech co., ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$5.20 |
52 Week High | NT$15.60 |
52 Week Low | NT$4.56 |
Beta | 1.52 |
11 Month Change | -63.25% |
3 Month Change | -63.89% |
1 Year Change | -65.33% |
33 Year Change | -73.71% |
5 Year Change | -91.41% |
Change since IPO | -91.33% |
Recent News & Updates
Shareholder Returns
6566 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | 0% | 0.7% | -1.4% |
1Y | -65.3% | 6.8% | 26.5% |
Return vs Industry: 6566 underperformed the TW Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: 6566 underperformed the TW Market which returned 20.3% over the past year.
Price Volatility
6566 volatility | |
---|---|
6566 Average Weekly Movement | 18.8% |
Pharmaceuticals Industry Average Movement | 3.5% |
Market Average Movement | 4.6% |
10% most volatile stocks in TW Market | 8.0% |
10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6566's share price has been volatile over the past 3 months.
Volatility Over Time: 6566's weekly volatility has increased from 12% to 19% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | n/a | Zhongguang Jian | www.cybiotech.com.tw |
Chuang Yi Biotech Co., ltd. engages in the research, development, and marketing of medicines and health foods in Taiwan. The company offers products in the areas of gastrointestinal, metabolism, and regular health care, as well as allergy reducing products.
Chuang Yi Biotech co., ltd. Fundamentals Summary
6566 fundamental statistics | |
---|---|
Market cap | NT$176.47m |
Earnings (TTM) | -NT$34.32m |
Revenue (TTM) | NT$252.41m |
0.7x
P/S Ratio-5.1x
P/E RatioIs 6566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6566 income statement (TTM) | |
---|---|
Revenue | NT$252.41m |
Cost of Revenue | NT$178.31m |
Gross Profit | NT$74.10m |
Other Expenses | NT$108.43m |
Earnings | -NT$34.32m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.01 |
Gross Margin | 29.36% |
Net Profit Margin | -13.60% |
Debt/Equity Ratio | 0% |
How did 6566 perform over the long term?
See historical performance and comparison